<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04905017</url>
  </required_header>
  <id_info>
    <org_study_id>DMS-10809</org_study_id>
    <nct_id>NCT04905017</nct_id>
  </id_info>
  <brief_title>Trisol System EFS Study</brief_title>
  <official_title>Early Feasibility Study of the Trisol System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trisol Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trisol Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this early feasibility study is to gain early clinical insight into Trisol&#xD;
      system safety and performance to treat patients with moderate or greater tricuspid&#xD;
      regurgitation (TR).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, single-arm, open-label, multi-center early feasibility clinical study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">July 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of device-related serious adverse events</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Rate of device-related serious adverse events, including death (cardiovascular and non- cardiovascular), MI (MVARC definitions), disabling stroke, life-threatening bleeding (MVARC type III-V), renal failure requiring dialysis, emergency surgery, need for additional surgical procedures due to device failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of technical success</measure>
    <time_frame>During procedure</time_frame>
    <description>Technical success: delivery and deployment of the device in the correct position and retrieval of the delivery system.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of procedural success</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Procedural success: freedom from emergency surgery or reintervention related to the device or access procedure, without death, stroke, or device dysfunction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in TR from baseline</measure>
    <time_frame>During procedure</time_frame>
    <description>Change in TR from baseline: reduction in TR grade immediately following implantation as compared to baseline TR grade, based on TEE imaging.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical performance endpoints - Change in TR from baseline</measure>
    <time_frame>At 30 days, 6 months, 12 months</time_frame>
    <description>Change in TR from baseline: reduction in TR grade as compared to baseline TR grade, based on TTE imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical performance endpoints - Change in NYHA class</measure>
    <time_frame>At 30 days, 6 months, 12 months, and then annually</time_frame>
    <description>New York Heart Association (NYHA) functional class: change in NYHA from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical performance endpoints --minute walk test</measure>
    <time_frame>At 30 days, 6 months and 12 months</time_frame>
    <description>Six-minute walk test: change in distance (m) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-of-Life: change from baseline as measured by Kansas City Cardiomyopathy Questionnaire</measure>
    <time_frame>At 30 days, 6 months and 12 months</time_frame>
    <description>Clinical performance endpoints -Quality-of-Life: change from baseline as measured by Kansas City Cardiomyopathy Questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Tricuspid Regurgitation</condition>
  <arm_group>
    <arm_group_label>Treatment with the Trisol System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter Tricuspid Valve Replacement</intervention_name>
    <description>Replacement of the tricusupid valve using Trisol System in a transcatheter approach</description>
    <arm_group_label>Treatment with the Trisol System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;18 years.&#xD;
&#xD;
          2. Subject meets the legal minimum age to provide informed consent based on local&#xD;
             regulatory requirements.&#xD;
&#xD;
          3. Participant has symptomatic, moderate or greater functional or degenerative tricuspid&#xD;
             regurgitation (TR) as determined by the Echocardiography Core Lab assessment of a&#xD;
             qualifying transthoracic echocardiogram (TTE) and/or transesophageal echocardiogram&#xD;
             (TEE).&#xD;
&#xD;
          4. New York Heart Association (NYHA) Functional Class II to IVa.&#xD;
&#xD;
          5. Participant is deemed at high surgical risk or greater for tricuspid valve surgery and&#xD;
             appropriate for transcatheter tricuspid valve replacement as determined by the local&#xD;
             Heart Team.&#xD;
&#xD;
          6. Participant adequately treated based upon medical standards, including for coronary&#xD;
             artery disease, mitral regurgitation, and Guideline-Directed Medical Therapy (GDMT)&#xD;
             for heart failure for at least 30-days prior to index procedure.&#xD;
&#xD;
          7. Male or non-pregnant female.&#xD;
&#xD;
          8. Participant understands the nature of the procedure and provides written informed&#xD;
             consent prior to any study specific assessments.&#xD;
&#xD;
          9. Participant is willing and able to comply with the specified study requirements and&#xD;
             follow-up evaluations.&#xD;
&#xD;
         10. Participant is anatomically suitable for the Trisol system, including trans-jugular&#xD;
             access as per imaging requirements, and is approved by the Subject Screening Committee&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous tricuspid valve repair or replacement which may impede proper study device&#xD;
             delivery or deployment.&#xD;
&#xD;
          2. Stroke or transient ischemic event within the previous 90 days.&#xD;
&#xD;
          3. Acute myocardial infarction within the previous 90 days.&#xD;
&#xD;
          4. Hemodynamic instability requiring inotropic therapy or mechanical hemodynamic support&#xD;
             devices.&#xD;
&#xD;
          5. Untreated clinically significant coronary artery disease requiring revascularization.&#xD;
&#xD;
          6. Implant or revision of any rhythm management device (CRT or CRT-D) or implantable&#xD;
             cardioverter-defibrillator within the previous 30 days.&#xD;
&#xD;
          7. New or untreated right heart chamber or/and superior vena cava intracardiac mass,&#xD;
             thrombus, or vegetation.&#xD;
&#xD;
          8. Systolic pulmonary arterial pressure (sPAP) &gt; 80 mmHg as measured by pulmonary&#xD;
             pressure catheter.&#xD;
&#xD;
          9. Severe RV dysfunction with RV Stroke Work Index (RVSWI) g/m2/beat &lt;400 and Pulmonary&#xD;
             Artery Pulsatile index (PAPi) &lt;2.&#xD;
&#xD;
         10. Ongoing sepsis, including active endocarditis.&#xD;
&#xD;
         11. Active infection requiring current antibiotic therapy.&#xD;
&#xD;
         12. Known bleeding diathesis or hypercoagulable state.&#xD;
&#xD;
         13. Blood dyscrasias as defined: leukopenia (WBC &lt;3000 cells/mm3), thrombocytopenia&#xD;
             (platelet count &lt;50,000 cells/mm3).&#xD;
&#xD;
         14. Active gastrointestinal (GI) bleeding or history of GI bleed within the previous 60&#xD;
             days that would preclude anticoagulation.&#xD;
&#xD;
         15. LVEF &lt;25% as measured by resting echocardiogram within 30 days prior to index&#xD;
             procedure.&#xD;
&#xD;
         16. Patients in whom transesophageal echocardiography is contraindicated.&#xD;
&#xD;
         17. Aortic, mitral or pulmonary valve disease (severe stenosis or severe regurgitation)&#xD;
             requiring intervention or performed within 90 days prior to enrollment.&#xD;
&#xD;
         18. Severe tricuspid valve stenosis.&#xD;
&#xD;
         19. Need for any percutaneous cardiovascular intervention, cardiovascular surgery, or&#xD;
             carotid surgery within 30 days prior to index procedure.&#xD;
&#xD;
         20. Need for emergent or urgent non cardiac surgery for any reason.&#xD;
&#xD;
         21. Contraindication or known allergy to device components, anticoagulation therapy with a&#xD;
             vitamin K antagonist, or to contrast media that cannot be adequately premedicated.&#xD;
&#xD;
         22. History of cardiac transplantation, or participant currently listed for urgent&#xD;
             transplant (e.g., UNOS Status 1).&#xD;
&#xD;
         23. Presence of any known life-threatening non-cardiac disease that will limit the&#xD;
             subject's life expectancy to less than one year.&#xD;
&#xD;
         24. Contraindication or known hypersensitivity to anticoagulant therapy and/or&#xD;
             antiplatelet therapy.&#xD;
&#xD;
         25. Venous anatomy unsuitable for implant delivery.&#xD;
&#xD;
         26. Pacemaker or ICD lead present that would prevent appropriate valve placement.&#xD;
&#xD;
         27. Active COVID-19 infection.&#xD;
&#xD;
         28. Comorbid condition(s) that, in the opinion of the investigator, could limit the&#xD;
             patient's ability to participate in the study, including compliance with follow-up&#xD;
             requirements, or that could impact the scientific integrity of the study.&#xD;
&#xD;
         29. Previously enrolled in this study or currently participating in another&#xD;
             investigational drug or device study that has not completed the primary endpoint or&#xD;
             that clinically interferes with the endpoints of this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isaac George, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ron Davidson, B. Sc., MBA</last_name>
    <phone>+972 528998866</phone>
    <email>rond@trisol-medical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Columbia University Medical Center/NYPH</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kate Dalton, MS, RD</last_name>
      <phone>347-514-3366</phone>
      <email>keb2114@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cardiology</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Linda Bailes Bryceland, RN</last_name>
      <phone>434-982-1058</phone>
      <email>SL9PC@virginia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 20, 2021</study_first_submitted>
  <study_first_submitted_qc>May 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

